Peginterferon-α-2a
1
Reactions 1390 - 25 Feb 2012 S Peginterferon-α-2a Thrombotic microangiopathy in an elderly patient: case report A 69-year-old man developed thrombotic microangiopathy while receiving peginterferon-α-2a. He subsequently died. The man received SC peginterferon-α-2a 180µg, followed by 135µg weekly, for a hepatitis C infection. Two months later, he presented with dyspnoea and chest pain. Chest x-ray revealed reticulonodular opacification. Pneumonitis was suspected; however, he subsequently deteriorated and developed hypoxia by day 7 after admission. He received ventilation and methylprednisolone. On day 10, his respiratory function had improved; however, his haemoglobin level decreased to 6.6 g/dL. He received a blood transfusion. On day 13, analysis revealed a bilirubin level of 39 µmol/L, an LDH level of 2505 IU/L, impaired renal function, blood and protein in his urine, and red cell fragments in a blood film. He received a plasma exchange; however, he deteriorated further, and died on day 14. Subsequently, an ADAMTS13 activity assay was found to be normal, and he was diagnosed with thrombotic microangiopathy. Iskander D, et al. Thrombotic microangiopathy complicating pegylated interferon treatment of hepatitis C infection. American Journal of Hematology 86: 859, No. 10, Oct 2011. Available from: URL: http://dx.doi.org/10.1002/ajh.22057 - United Kingdom 803067331 1 Reactions 25 Feb 2012 No. 1390 0114-9954/10/1390-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Transcript of Peginterferon-α-2a
Reactions 1390 - 25 Feb 2012
SPeginterferon-α-2a
Thrombotic microangiopathy in an elderlypatient: case report
A 69-year-old man developed thromboticmicroangiopathy while receiving peginterferon-α-2a. Hesubsequently died.
The man received SC peginterferon-α-2a 180µg,followed by 135µg weekly, for a hepatitis C infection. Twomonths later, he presented with dyspnoea and chest pain.Chest x-ray revealed reticulonodular opacification.Pneumonitis was suspected; however, he subsequentlydeteriorated and developed hypoxia by day 7 afteradmission. He received ventilation andmethylprednisolone. On day 10, his respiratory functionhad improved; however, his haemoglobin level decreasedto 6.6 g/dL. He received a blood transfusion. On day 13,analysis revealed a bilirubin level of 39 µmol/L, an LDHlevel of 2505 IU/L, impaired renal function, blood andprotein in his urine, and red cell fragments in a blood film.He received a plasma exchange; however, he deterioratedfurther, and died on day 14. Subsequently, anADAMTS13 activity assay was found to be normal, and hewas diagnosed with thrombotic microangiopathy.Iskander D, et al. Thrombotic microangiopathy complicating pegylated interferontreatment of hepatitis C infection. American Journal of Hematology 86: 859, No.10, Oct 2011. Available from: URL: http://dx.doi.org/10.1002/ajh.22057 - UnitedKingdom 803067331
1
Reactions 25 Feb 2012 No. 13900114-9954/10/1390-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
![Ursinyova, N. , Bedford, R. B., & Gallagher, T. (2016). Copper- … · alkyl halides and (b) with key modifications including an external iodide sourcetoprovideboronicester 2a .[a]Enantiomericpurityof](https://static.fdocument.org/doc/165x107/607b466c804c7425625e49f3/ursinyova-n-bedford-r-b-gallagher-t-2016-copper-alkyl-halides.jpg)
